Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes.
Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, Nanni M, Pescarmona E, Mancini F, Pulsoni A, Martelli M, Di Rocco A, Finolezzi E, Paoloni F, Mauro FR, Cuneo A, Guarini A, Foà R. Del Giudice I, et al. Among authors: di rocco a. Br J Haematol. 2012 Mar;156(5):601-11. doi: 10.1111/j.1365-2141.2011.08962.x. Epub 2011 Dec 8. Br J Haematol. 2012. PMID: 22150124 Free article.
MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
De Sanctis V, Finolezzi E, Osti MF, Grapulin L, Alfò M, Pescarmona E, Berardi F, Natalino F, Moleti ML, Di Rocco A, Enrici RM, Foà R, Martelli M. De Sanctis V, et al. Among authors: di rocco a. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1154-60. doi: 10.1016/j.ijrobp.2008.02.036. Epub 2008 May 9. Int J Radiat Oncol Biol Phys. 2008. PMID: 18472357 Clinical Trial.
Diffuse large B-cell lymphoma.
Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Martelli M, et al. Among authors: di rocco a. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71. doi: 10.1016/j.critrevonc.2012.12.009. Epub 2013 Jan 30. Crit Rev Oncol Hematol. 2013. PMID: 23375551 Review.
Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.
Nobili S, Napoli C, Puccini B, Landini I, Perrone G, Brugia M, Benelli G, Doria M, Martelli M, Finolezzi E, Di Rocco A, Del Fava E, Rigacci L, Di Lollo S, Bosi A, Mini E. Nobili S, et al. Among authors: di rocco a, di lollo s. Leuk Lymphoma. 2014 Sep;55(9):2071-8. doi: 10.3109/10428194.2013.866665. Epub 2014 Feb 24. Leuk Lymphoma. 2014. PMID: 24289107
Primary mediastinal lymphoma: diagnosis and treatment options.
Martelli M, Di Rocco A, Russo E, Perrone S, Foà R. Martelli M, et al. Among authors: di rocco a. Expert Rev Hematol. 2015 Apr;8(2):173-86. doi: 10.1586/17474086.2015.994604. Epub 2014 Dec 24. Expert Rev Hematol. 2015. PMID: 25537750 Review.
Primary mediastinal large B-cell lymphoma.
Martelli M, Ferreri A, Di Rocco A, Ansuinelli M, Johnson PWM. Martelli M, et al. Among authors: di rocco a. Crit Rev Oncol Hematol. 2017 May;113:318-327. doi: 10.1016/j.critrevonc.2017.01.009. Epub 2017 Jan 21. Crit Rev Oncol Hematol. 2017. PMID: 28318892 Review.
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Visco C, et al. Among authors: di rocco a. Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30407625 Free article. No abstract available.
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I, De Novi LA, Cavalli M, Novelli N, Soscia R, Genuardi E, Mantoan B, Drandi D, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei V, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: di rocco a. Hematol Oncol. 2020 Dec;38(5):698-704. doi: 10.1002/hon.2792. Epub 2020 Aug 28. Hematol Oncol. 2020. PMID: 32816326
227 results